FDA Reverses Decision: Agrees to Review Moderna's New mRNA Flu Vaccine

The FDA has flipped its stance and will now review Moderna's mRNA-1010 flu vaccine for adults 50+, after an initial rejection caused controversy. Decision sets August 5, 2026, target date.